Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b/2 study of MIL62 in lupus nephritis
CTR20211541Phase 2Active
- Sponsor
- Mabworks Biotech
- Start
- Dec 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of Bejescin in lupus nephritis (LN), sponsored by Mabworks Biotech. Started Dec 2021; status: active.
02
Drugs
Bejescin
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on CTR20211541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211541.